Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

SHTAC is critically appraising manufacturer’s submission to NICE on new drug for pulmonary embolism

Published: 4 December 2012
Rivaroxaban anticoagulant drug

SHTAC is assessing the clinical-effectiveness and cost-effectiveness of rivaroxaban for the treatment of pulmonary embolism for the National Institute for Health and Clinical Excellence (NICE) Single Technology Appraisal process.

SHTAC is preparing an evidence review for the National Institute for Health and Clinical Excellence (NICE) to inform their Single Technology Appraisal of the drug rivaroxaban for the treatment of acute symptomatic pulmonary embolism, with or without symptomatic deep vein thrombosis, and the prevention of recurrent venous thromboembolism.

Venous thromboembolism is a term used to describe how blood clots (thrombi) form in a vein and can break off (embolise) into the vascular system; it includes deep vein thrombosis (DVT) and pulmonary embolism. When dislodged thrombi travel to the lungs this is known as pulmonary embolism. Pulmonary embolism can cause sudden death and those who survive occasionally require intensive care, and recovery can take several weeks or months. Rivaroxaban is an anticoagulant drug that has been evaluated as an alternative to standard treatment with heparin and a vitamin K antagonist (e.g. warfarin) in patients with pulmonary embolism. NICE is expected to issue guidance on rivaroxaban to the health service in England and Wales in September 2013.

For more information on SHTAC's research into vascular diseases please visit our Research page.

Privacy Settings